ATE301657T1 - Azolo-pyrimidine - Google Patents

Azolo-pyrimidine

Info

Publication number
ATE301657T1
ATE301657T1 AT03075887T AT03075887T ATE301657T1 AT E301657 T1 ATE301657 T1 AT E301657T1 AT 03075887 T AT03075887 T AT 03075887T AT 03075887 T AT03075887 T AT 03075887T AT E301657 T1 ATE301657 T1 AT E301657T1
Authority
AT
Austria
Prior art keywords
azolo
pyrimidines
crf
psychiatric
immunological
Prior art date
Application number
AT03075887T
Other languages
English (en)
Inventor
Liqi He
Paul Gilligan
Robert Chorvat
Argyrios Georgios Arvanitis
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/015,002 external-priority patent/US6191131B1/en
Priority claimed from US09/015,001 external-priority patent/US6060478A/en
Priority claimed from US09/014,734 external-priority patent/US6313124B1/en
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of ATE301657T1 publication Critical patent/ATE301657T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
AT03075887T 1998-01-28 1999-01-28 Azolo-pyrimidine ATE301657T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/015,002 US6191131B1 (en) 1997-07-23 1998-01-28 Azolo triazines and pyrimidines
US09/015,001 US6060478A (en) 1996-07-24 1998-01-28 Azolo triazines and pyrimidines
US09/014,734 US6313124B1 (en) 1997-07-23 1998-01-28 Tetrazine bicyclic compounds

Publications (1)

Publication Number Publication Date
ATE301657T1 true ATE301657T1 (de) 2005-08-15

Family

ID=27360164

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03075887T ATE301657T1 (de) 1998-01-28 1999-01-28 Azolo-pyrimidine
AT99904382T ATE264860T1 (de) 1998-01-28 1999-01-28 Pyrazolotriazine als crf antagonisten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99904382T ATE264860T1 (de) 1998-01-28 1999-01-28 Pyrazolotriazine als crf antagonisten

Country Status (19)

Country Link
EP (2) EP1344779B1 (de)
JP (1) JP4228332B2 (de)
KR (1) KR100574313B1 (de)
CN (2) CN1542010A (de)
AT (2) ATE301657T1 (de)
AU (1) AU748818C (de)
BR (1) BR9908206A (de)
CA (2) CA2314613C (de)
DE (2) DE69916578T2 (de)
DK (2) DK1344779T3 (de)
ES (2) ES2247478T3 (de)
IL (1) IL137019A0 (de)
NZ (2) NZ505079A (de)
PL (1) PL200939B1 (de)
PT (2) PT1344779E (de)
SG (1) SG111076A1 (de)
SI (2) SI1344779T1 (de)
TW (1) TW520372B (de)
WO (1) WO1999038868A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059907A2 (en) * 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
OA12050A (en) 1999-09-30 2006-05-02 Neurogen Corp Certain alkylene diamine-substituted heterocycles.
HUP0202678A3 (en) 1999-09-30 2004-06-28 Pfizer Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines, pharmaceutical compositions containing them and their use
US6525067B1 (en) 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
ES2214422T3 (es) * 2000-05-18 2004-09-16 Neurocrine Biosciences, Inc. Antagonistas del receptor de crf y metodos relacionados.
CA2417661A1 (en) * 2000-08-02 2002-02-07 Malope Company Limited Diagnosis and treatment of non-ulcer dyspepsia based on hypothalamic-pituitary-adrenal axis abnormality
IL157615A0 (en) 2001-03-13 2004-03-28 Bristol Myers Squibb Co 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
US7034023B2 (en) * 2003-04-04 2006-04-25 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
US7056920B2 (en) 2003-04-04 2006-06-06 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
US20070293511A1 (en) * 2003-12-22 2007-12-20 Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation Crf Receptor Antagonists and Methods
MY143499A (en) * 2003-12-22 2011-05-31 Sb Pharmco Inc Crf receptor antagonist and methods relating thereto
EP1722826A2 (de) * 2004-02-13 2006-11-22 SB Pharmco Puerto Rico Inc. Crf-rezeptor-antagonisten, deren herstellung, deren pharmazeutische zusammensetzung und deren verwendung
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
US7851468B2 (en) * 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
US10166271B2 (en) 2006-06-21 2019-01-01 The Regents Of The University Of California Methods for promoting hair growth
US8513276B2 (en) 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
HRP20150642T1 (hr) 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
EP3610890A1 (de) 2012-11-14 2020-02-19 The Johns Hopkins University Verfahren und zusammensetzungen zur behandlung von schizophrenie
CN104876935B (zh) * 2015-05-18 2017-04-19 南方医科大学 2‑氨基吡咯并[1,2‑f][1,2,4]三嗪类化合物、合成方法及应用
RU2712196C2 (ru) * 2015-06-24 2020-01-24 Куровир Аб Производные пиразоло[1,5-a]триазин-4-амина, применимые в терапии
EP3630763A4 (de) * 2017-08-14 2021-03-10 Spruce Biosciences, Inc. Corticotropinfreisetzungsfaktor-rezeptorantagonisten
WO2019036503A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
CN112028891B (zh) * 2019-07-30 2022-07-05 厦门宝太生物科技股份有限公司 腺苷受体拮抗剂
CN116322544B (zh) 2020-08-12 2024-08-02 云杉生物科学公司 用于治疗多囊卵巢综合征的方法和组合物
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US6020492A (en) * 1995-05-12 2000-02-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
CZ244598A3 (cs) * 1996-02-07 1998-10-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidiny jako antagonisty CRF receptoru
ATE375344T1 (de) * 1996-07-24 2007-10-15 Bristol Myers Squibb Pharma Co Azolotriazine und pyrimidine
CZ68199A3 (cs) * 1996-08-28 1999-11-17 Pfizer Inc. 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob

Also Published As

Publication number Publication date
KR20010040426A (ko) 2001-05-15
DE69916578T2 (de) 2005-03-31
AU748818C (en) 2003-11-20
HK1060348A1 (en) 2004-08-06
NZ505079A (en) 2003-08-29
IL137019A0 (en) 2001-06-14
DE69926665D1 (de) 2005-09-15
CN1289335A (zh) 2001-03-28
TW520372B (en) 2003-02-11
DE69926665T2 (de) 2006-06-08
EP1049699A1 (de) 2000-11-08
KR100574313B1 (ko) 2006-04-27
PT1049699E (pt) 2004-08-31
CA2314613A1 (en) 1999-08-05
AU748818B2 (en) 2002-06-13
EP1344779A1 (de) 2003-09-17
JP2002501922A (ja) 2002-01-22
SI1049699T1 (en) 2004-10-31
CN1542010A (zh) 2004-11-03
ES2218991T3 (es) 2004-11-16
EP1344779B1 (de) 2005-08-10
AU2478799A (en) 1999-08-16
EP1049699B1 (de) 2004-04-21
CA2614603C (en) 2011-08-16
DE69916578D1 (de) 2004-05-27
PL342183A1 (en) 2001-05-21
PT1344779E (pt) 2005-10-31
SG111076A1 (en) 2005-05-30
NZ524842A (en) 2003-10-31
CA2614603A1 (en) 1999-08-05
CN1137123C (zh) 2004-02-04
JP4228332B2 (ja) 2009-02-25
BR9908206A (pt) 2000-12-05
ES2247478T3 (es) 2006-03-01
WO1999038868A1 (en) 1999-08-05
PL200939B1 (pl) 2009-02-27
SI1344779T1 (sl) 2006-02-28
CA2314613C (en) 2009-12-08
DK1049699T3 (da) 2004-07-05
ATE264860T1 (de) 2004-05-15
DK1344779T3 (da) 2005-09-05

Similar Documents

Publication Publication Date Title
ATE301657T1 (de) Azolo-pyrimidine
LV12292A (lv) Triazinu un pirimidinu azoloatvasinajumi
ATE255896T1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
MY132871A (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
LV12262A (lv) Ar arilaminu kondenseti piridini un pirimidini
CY1106607T1 (el) 4-(2-βουτυλαμιονο)-2,7-διμεθυλ-8-(2-μεθυλ-6-μεθοξυπυριδ-3-υλ) πυραζολο-1,5-αι-1,3,5-τριαζινη, τα εναντιομορα και φαρμακευτικως παραδεκτα αλατα αυτης ως συναρμοτες του υποδοχεα του παραγοντος απελευθερωσης κορτικοτροπινης
DK0674641T3 (da) Pyrrolopyrimidiner som CRF-antagonister
PT1140929E (pt) 1h-imidazo¬4,5-d|piridazin-7-onas 3h-imidazo¬4,5-c|piridin-4-onas e as tionas correspondentes como ligandos receptores do factor de libertacao de corticotrofina (flc)
ATE198895T1 (de) Verwendung von bindungsreagenzien gegen cd23 in der behandlung von autoimmunkrankheiten
WO2002004453A3 (en) PYRROLO[3,4-d]PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
MY141752A (en) Pyrazolotriazines as crf antagonists
MY141976A (en) Azolo triazines and pyrimidines
MY141511A (en) Azolo triazines and pyrimidines
CA2532925A1 (en) Azolo triazines and pyrimidines
Manelis et al. Neuropsychological model of brain organization of higher psychic functions in children suffering bronchial asthma

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1344779

Country of ref document: EP